Compare ADP & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADP | VRTX |
|---|---|---|
| Founded | 1949 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | EDP Services |
| Sector | Technology | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 102.9B | 96.6B |
| IPO Year | N/A | 1991 |
| Metric | ADP | VRTX |
|---|---|---|
| Price | $266.13 | $452.76 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 12 | 25 |
| Target Price | $312.25 | ★ $494.64 |
| AVG Volume (30 Days) | ★ 2.2M | 1.4M |
| Earning Date | 01-28-2026 | 11-03-2025 |
| Dividend Yield | ★ 2.56% | N/A |
| EPS Growth | ★ 8.22 | N/A |
| EPS | 10.13 | ★ 14.22 |
| Revenue | ★ $20,903,400,000.00 | $11,723,300,000.00 |
| Revenue This Year | $6.88 | $11.01 |
| Revenue Next Year | $5.78 | $8.74 |
| P/E Ratio | ★ $26.27 | $31.78 |
| Revenue Growth | 7.07 | ★ 10.33 |
| 52 Week Low | $247.18 | $362.50 |
| 52 Week High | $329.93 | $519.68 |
| Indicator | ADP | VRTX |
|---|---|---|
| Relative Strength Index (RSI) | 59.91 | 59.92 |
| Support Level | $256.83 | $433.81 |
| Resistance Level | $262.76 | $463.85 |
| Average True Range (ATR) | 4.12 | 10.71 |
| MACD | 2.04 | 0.51 |
| Stochastic Oscillator | 98.78 | 72.53 |
Automatic Data Processing is a global technology company providing cloud-based human capital management solutions, enabling clients to better implement payroll, talent, time, tax, and benefits administration. Additionally, ADP provides human resource outsourcing solutions that permit customers to offload some of their traditional HR tasks. The company operates through two segments: employer services and professional employer organization services. Employer services consist of the company's HCM products as well as a la carte HRO solutions. PEO services contain ADP's comprehensive HRO solution, where it acts as a co-employer with its customer. As of fiscal 2025, ADP serves over 1.1 million clients and pays over 42 million workers across 140 countries.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.